Skip to main content

Cervical Intraepithelial Neoplasia Grade 2/3

0
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Becton Dickinson
Becton DickinsonFRANKLIN LAKES, NJ
2 programs
BD Onclarity HPV AssayN/A
BD Onclarity™ HPV assayN/A1 trial
Active Trials
NCT04788849Completed300Est. Jul 2021
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
2 programs
Cytological screening in A1 and A3N/A1 trial
Frequent information of cytological/ HPV DNA screening resultsN/A1 trial
Active Trials
NCT02149030Active Not Recruiting6,958Est. Jan 2025
NCT04755517Enrolling By Invitation14,000Est. Dec 2025
Papivax
PapivaxTaiwan - Taipei
1 program
PVX4 Combination ProductPHASE_21 trial
Active Trials
NCT07454915Not Yet Recruiting138Est. Jun 2028
Asieris Pharmaceuticals
1 program
Cevira®PHASE_31 trial
Active Trials
NCT04484415Unknown402Est. Dec 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Asieris PharmaceuticalsCevira®
PapivaxPVX4 Combination Product
Becton DickinsonBD Onclarity™ HPV assay
UNION therapeuticsFrequent information of cytological/ HPV DNA screening results
UNION therapeuticsCytological screening in A1 and A3

Clinical Trials (5)

Total enrollment: 21,798 patients across 5 trials

NCT04484415Asieris PharmaceuticalsCevira®

Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)

Start: Nov 2020Est. completion: Dec 2023402 patients
Phase 3Unknown
NCT07454915PapivaxPVX4 Combination Product

PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia

Start: Mar 2026Est. completion: Jun 2028138 patients
Phase 2Not Yet Recruiting
NCT04788849Becton DickinsonBD Onclarity™ HPV assay

Extended VALidation of HUman Papillomavirus Assays and Collection DEvices for HPV Testing on Self-samples

Start: Mar 2021Est. completion: Jul 2021300 patients
N/ACompleted
NCT04755517UNION therapeuticsFrequent information of cytological/ HPV DNA screening results

Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400)

Start: Jun 2020Est. completion: Dec 202514,000 patients
N/AEnrolling By Invitation
NCT02149030UNION therapeuticsCytological screening in A1 and A3

Effectiveness of Cervical Screening in HPV Vaccinated Women

Start: Mar 2014Est. completion: Jan 20256,958 patients
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.